Denali Therapeutics
DNLI
18.45
+0.25
+1.37%
Denali Therapeutics
US · DNLI
#2454 by market cap
Listed 2017
18.45
+0.25
+1.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $31Market Newswire · 2026/7/15
-
Rating change
B. Riley Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35Market Newswire · 2026/8/25
-
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $37Market Newswire · 2026/11/13
-
Rating change
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $39Market Newswire · 2026/5/11
-
Rating change
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36Market Newswire · 2026/7/23
-
Rating change
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/5/26
-
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $24 to $42Market Newswire · 2026/11/5
-
Rating change
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $29Market Newswire · 2026/7/13
-
Rating change
UBS Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/6/16
-
Rating change
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41Market Newswire · 2026/8/7
-
Rating change
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $40Market Newswire · 2026/5/14
-
Rating change
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/7/13
-
Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q3 Revenue $17.8M, Vs. FactSet Est of $12.2MMT Newswires · 2026/11/4
-
Rating change
Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35Market Newswire · 2026/7/16
-
GUIDANCE: (DNLI) Denali Therapeutics Inc. Expects Q4 Revenue Range $30.0M - $32.0MMT Newswires · 2026/11/4
-
Rating change
Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/7/13
-
Rating change
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42Market Newswire · 2026/8/8
-
Rating change
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29Market Newswire · 2026/8/11
-
Rating change
Oppenheimer Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/5/11
-
Wells Fargo Initiates Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $35Market Newswire · 2026/11/13
-
Rating change
William Blair Maintains Denali Therapeutics(DNLI.US) With Buy RatingMarket Newswire · 2026/5/9
-
Rating change
Analysts Offer Insights on Healthcare Companies: Agilon Health (AGL), CG Oncology, Inc. (CGON) and Denali Therapeutics (DNLI)TipRanks · 2026/5/9
-
Rating change
Baird Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34Market Newswire · 2026/4/7
-
Rating change
Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $23Market Newswire · 2026/5/8
-
Rating change
TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy RatingMarket Newswire · 2026/5/9
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Denali Therapeutics discussion 0 comments